Abstract 49P
Background
Numb is a protein involved in asymmetric cell division determining cell fate across various research fields such as developmental neurobiology and cancer biology; however, its role remains poorly understood regarding brain metastases formation specifically within lung adenocarcinoma (LUAD).
Methods
In our previous study, five potential biomarkers for brain metastasis (BM) were identified using proteomic comparison of brain metastatic H1975-BrM cells and parent H1975 cells. We utilized the Cancer Genome Atlas Program (TCGA) database to analyze five genes expression at the level of mRNA in LUAD. Univariate and multivariate analyses were used to select independent risk factors that affect the prognosis of LUAD, and a nomogram model was established. The relationship between NUMB expression and LUAD immune infiltration was analyzed using TIMER, GEPIA database and TCGA data sets. In addition, clinical validation was performed using immunohistochemical (IHC) staining of lung tumor tissue from patients (n = 50) and investigated the relationship between NUMB and clinicopathology and prognosis in LUAD. The q-PCR and Western-blot assays were used to validate the expression of NUMB in vitro.
Results
After analyzing the prognostic value of those 5 differentially expressed genes, NUMB was the only gene associated with multiple prognostic indicators in LUAD patients using TCGA public database. Analysis of GEPIA datasets revealed that high NUMB expression in LUAD tissues correlates with poor patient survival. Multivariate analysis showed that Pathologic T stage, N stage, and high level of NUMB protein were independent prognostic factors of overall survival in patients with LUAD. These factors were used to construct the nomogram model. The analysis of TIMER, GEPIA database and TCGA data sets showed that the expression level of NUMB was negatively correlated with B cells, NK cells and Cytotoxic cells. Furthermore, NUMB was highly expressed in brain metastatic H1975-BrM cell line.
Conclusions
Our findings demonstrate that NUMB serves as an independent potential prognostic biomarker implicated not only in immune infiltration of LUAD, but also closely correlates with BM development.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
142P - Lipidomic signature in response to omega-3 fatty acids and γ-linolenic acid supplementation in breast cancer patients receiving aromatase inhibitors
Presenter: Vesna Vucic
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
Presenter: Simone Rota
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Is it time to incorporate next generation sequencing of body fluids for detection of circulating tumor DNA (ctDNA) alterations?
Presenter: Aditya Shreenivas
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Unveiling the molecular landscape of head and neck cancer: Pathway dysregulations and potential therapeutic targets
Presenter: Rajeev Vijayakumar
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - ESR1 fusions as potential mechanism of resistance to endocrine therapy in metastatic breast cancer
Presenter: Sewanti Limaye
Session: Cocktail & Poster Display session
Resources:
Abstract
147P - Clinical characteristics and outcomes in non-small cell lung cancer patients harboring rare mutations: A single center real-world data
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Diversity of genomic mechanisms of resistance to endocrine therapy in ER+ breast cancer
Presenter: Prithika Sritharan
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Assessing treatment options for gynaecological cancers (GC) using next-generation sequencing (NGS): A real-world analysis
Presenter: Álvaro García
Session: Cocktail & Poster Display session
Resources:
Abstract
150P - Prevalence of DPYD variants in 1478 cancer patients receiving fluoropyrimidine chemotherapy: A real-world data analysis
Presenter: Bahaaeldin Baraka
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Unravelling the limitations of next-generation sequencing (NGS)-based liquid biopsy (LB) across solid tumors: The PREICO-LB project
Presenter: Cinta Hierro
Session: Cocktail & Poster Display session
Resources:
Abstract